King's College London

Research portal

GPCR targets in type 2 diabetes

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

Original languageEnglish
Title of host publicationGPCRs
Subtitle of host publicationStructure, Function, and Drug Discovery
Number of pages25
ISBN (Electronic)9780128162286
Published1 Jan 2019

King's Authors


Approximately 400 million people worldwide currently have type 2 diabetes (T2D), in which peripheral cells show reduced sensitivity to insulin and islet β-cells do not secrete sufficient insulin to maintain low blood glucose levels. There are a range of therapies in current clinical use to treat T2D, but surprisingly few are GPCR ligands. This chapter reviews the current GPCR-based therapies for T2D, and provides information on potential future candidates that have arisen through GPCR research in insulin-secreting β-cells or insulin target tissues, and on GPCR ligands that are undergoing clinical trials. We also provide a future perspective on GPCR-based T2D therapeutic approaches, emphasizing the importance of refining and discovering new ways to treat T2D to improve the quality of life of individuals with diabetes.

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454